Skip to main content

Advertisement

Log in

Cholinergic balance in dementia with Lewy bodies: reversible worsening of Parkinsonism at rivastigmine dosage modulation

  • Case Report
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

We describe a patient with probable dementia with Lewy bodies (DLB) whose Parkinsonism worsened after administration of rivastigmine within the therapeutic dose range. Some extrapyramidal signs (EPS) then reversed to pre-treatment level after rivastigmine dose reduction. We draw attention to the need of EPS monitoring during titration of cholinesterase inhibitors in patients with DLB. This is the first report to our knowledge of iatrogenic worsening of Parkinsonism which was successfully managed by dose reduction.

Sommario

Si descrive il caso di un paziente affetto da Demenza a corpi di Lewy (Dementia with Lewy Bodies, DLB) probabile, in cui si è assistito ad un peggioramento del parkinsonismo dopo somministrazione di rivastigmina a dosi terapeutiche. Alcuni segni extrapiramidali sono regrediti al livello pre-trattamento con una riduzione posologica di rivastigmina. Si sottolinea la necessità di un monitoraggio dei segni extrapiramidali durante la titolazione della terapia con inibitori dell’acetilcolinesterasi cerebrale in pazienti con DLB. Questo è il primo caso descritto, a nostra conoscenza, di un peggioramento iatrogeno di parkinsonismo efficacemente gestito con una riduzione posologica della terapia con rivastigmina.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Lippa CF, Duda JE, Grossman M et al (2007) DLB and PDD boundary issues. Neurology 68:812–819

    Article  PubMed  CAS  Google Scholar 

  2. Duda JE (2004) Pathology and neurotransmitter abnormalities of dementia with Lewy bodies. Dement Geriatr Cogn Disord 17[Suppl 1]:3–14

    Article  PubMed  CAS  Google Scholar 

  3. Shea C, MacKnight C, Rockwood K (1998) Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 10:229–238

    Article  PubMed  CAS  Google Scholar 

  4. Thomas AJ, Burn DJ, Rowan EN et al (2005) A comparison of the efficacy of donepezil in Parkinson’s disease with dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 20:938–944

    Article  PubMed  Google Scholar 

  5. McKeith IG, Dickson DW, Lowe J et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872

    Article  PubMed  CAS  Google Scholar 

  6. Ballard C, O’Brien J, Swann A et al (2000) One year follow-up of parkinsonism in dementia with Lewy bodies. Dement Geriatr Cogn Disord 11:219–222

    Article  PubMed  CAS  Google Scholar 

  7. McKeith I, Del Ser T, Spano P et al (2000) Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356:2031–2036

    Article  PubMed  CAS  Google Scholar 

  8. Onofrj M, Thomas A (2003) Severe worsening of parkinsonism in Lewy body dementia due to donepezil. Neurology 61:1452

    PubMed  Google Scholar 

  9. Emre M, Aarsland D, Albanese A et al (2004) Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 351:2509–2518

    Article  PubMed  CAS  Google Scholar 

  10. Iseki E (2004) Dementia with Lewy bodies: reclassification of pathological subtypes and boundary with Parkinson’s disease or Alzheimer’s disease. Neuropathology 24:72–78

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to F. Clerici.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clerici, F., Ratti, P.L., Pomati, S. et al. Cholinergic balance in dementia with Lewy bodies: reversible worsening of Parkinsonism at rivastigmine dosage modulation. Neurol Sci 28, 282–284 (2007). https://doi.org/10.1007/s10072-007-0837-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-007-0837-6

Key words

Navigation